Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Assets: 2016-2025

Historic Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $368.0 million.

  • Rocket Pharmaceuticals' Assets fell 6.52% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $368.0 million, marking a year-over-year decrease of 6.52%. This contributed to the annual value of $527.7 million for FY2024, which is 6.82% down from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Assets is $368.0 million, which was down 12.58% from $421.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Assets ranged from a high of $598.8 million in Q3 2023 and a low of $368.0 million during Q3 2025.
  • For the 3-year period, Rocket Pharmaceuticals' Assets averaged around $479.0 million, with its median value being $471.1 million (2025).
  • In the last 5 years, Rocket Pharmaceuticals' Assets spiked by 58.05% in 2021 and then tumbled by 34.25% in 2024.
  • Rocket Pharmaceuticals' Assets (Quarterly) stood at $497.0 million in 2021, then rose by 11.02% to $551.8 million in 2022, then increased by 2.63% to $566.3 million in 2023, then decreased by 6.82% to $527.7 million in 2024, then fell by 6.52% to $368.0 million in 2025.
  • Its Assets was $368.0 million in Q3 2025, compared to $421.0 million in Q2 2025 and $471.1 million in Q1 2025.